Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Fulham

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Journal of Medical Imaging and Radiation Oncology|March 27, 2018
Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphomaVicky Chin, Michael Fulham, Mark Hertzberg, et al.
Head & Neck|December 17, 2008
Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancerRichard C W Martin, Michael Fulham, Kerwin F Shannon, et al.
Hemasphere|February 27, 2023
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 StudyJudith Trotman, Peter Presgrave, Duncan P Carradice, et al.
American Journal of Respiratory and Critical Care Medicine|June 16, 2015
A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural MesotheliomaSteven C Kao, Michael Fulham, Kirby Wong, et al.
RSC Medicinal Chemistry|August 6, 2021
Synthesis and pharmacological evaluation of [<sup>18</sup>F]PBR316: a novel PET ligand targeting the translocator protein 18 kDa (TSPO) with low binding sensitivity to human single nucleotide polymorphism rs6971Filomena Mattner, Andrew Katsifis, Thomas Bourdier, et al.
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participantsJudith Trotman, Marion Fournier, Thierry Lamy, et al.
Human Brain Mapping|October 23, 2023
T1 and FLAIR signal intensities are related to tau pathology in dominantly inherited Alzheimer diseaseFarzaneh Rahmani, Matthew R Brier, Brian A Gordon, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|July 14, 2021
Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's diseaseOphir Keret, Adam M Staffaroni, John M Ringman, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 9, 2019
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studiesYi Su, Shaney Flores, Guoqiao Wang, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Journal of Medical Imaging and Radiation Oncology|March 27, 2018
Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphomaVicky Chin, Michael Fulham, Mark Hertzberg, et al.
Head & Neck|December 17, 2008
Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancerRichard C W Martin, Michael Fulham, Kerwin F Shannon, et al.
Hemasphere|February 27, 2023
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 StudyJudith Trotman, Peter Presgrave, Duncan P Carradice, et al.
American Journal of Respiratory and Critical Care Medicine|June 16, 2015
A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural MesotheliomaSteven C Kao, Michael Fulham, Kirby Wong, et al.
RSC Medicinal Chemistry|August 6, 2021
Synthesis and pharmacological evaluation of [<sup>18</sup>F]PBR316: a novel PET ligand targeting the translocator protein 18 kDa (TSPO) with low binding sensitivity to human single nucleotide polymorphism rs6971Filomena Mattner, Andrew Katsifis, Thomas Bourdier, et al.
The New England Journal of Medicine|June 23, 2016
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's LymphomaPeter Johnson, Massimo Federico, Amy Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participantsJudith Trotman, Marion Fournier, Thierry Lamy, et al.
Human Brain Mapping|October 23, 2023
T1 and FLAIR signal intensities are related to tau pathology in dominantly inherited Alzheimer diseaseFarzaneh Rahmani, Matthew R Brier, Brian A Gordon, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|July 14, 2021
Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's diseaseOphir Keret, Adam M Staffaroni, John M Ringman, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 9, 2019
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studiesYi Su, Shaney Flores, Guoqiao Wang, et al.
Pageof 11